Statins may have a role in reducing the risk of dying from four common cancers, a European conference has been told.
Researchers at Aston University, UK, found that patients diagnosed with high cholesterol had a reduced risk of developing cancer – and say that treatment with statins may be responsible.
The researchers found that patients diagnosed with high cholesterol and who took medication to reduce it had a 47% lower risk of death from prostate cancer, 43% lower risk of death from breast cancer, 30% lower risk of death from bowel cancer, and 22% lower risk of death of lung cancer.
Dr Paul Carter from the ACALM Study Unit at Aston Medical School, Aston University in Birmingham, England, told delegates at the Frontiers in CardioVascular Biology (FCVB) 2016 in Florence that its research showed that a high cholesterol diagnosis resulted in a “striking” reduction in mortality from the cancers.
“Based on previous research we think there’s a very strong possibility that statins are producing this effect,” he said.
“We previously found an association between having high cholesterol and developing breast cancer. Animal studies show that giving statins for high cholesterol can reduce the risk of breast cancer. We wanted to see if there was any effect of high cholesterol on mortality amongst cancer patients.”
The current study examined the link between high cholesterol and mortality in patients with lung, breast, prostate and bowel cancer and used data from patients admitted to UK hospitals with these cancers between 1 January, 2000, and 31 March, 2013, from the Algorithm for Comorbidities, Associations, Length of stay and Mortality (ACALM) clinical database. Mortality data was obtained from the Office for National Statistics.
Out of 929,552 patients in the ACALM study, 7,997 had lung cancer, 5,481 had breast cancer, 4,629 had prostate cancer, and 4,570 had bowel cancer.
“Our research suggests that there’s something about having a high cholesterol diagnosis that improves survival and the extent to which it did that was quite striking in the four cancers studied,” explained Dr Carter.
“Based on previous research we think there’s a very strong possibility that statins are producing this effect. These findings are likely to be seen in other cancers as well but this is only speculation and would need to be confirmed by studies in different types of cancer.”
Dr Rahul Potluri, senior author and founder of the ACALM Study Unit, said: "Statins have some of the best mortality evidence amongst all cardiovascular medications and statin use in patients with a diagnosis of high cholesterol is possibly the main reason that this diagnosis appears to be protective against death in patients with lung, breast, prostate and bowel cancer.
“Other cardiovascular medications may also be protective and explain the varying levels of risk reduction in the four cancer types. For example, prostate cancer is associated with heart disease and these patients tend to take ACE inhibitors and beta-blockers.”
He said the results of the study strengthen the argument for a clinical trial evaluating the possible protective effect of statins and other routinely used cardiovascular medications such as aspirin, blood pressure medications, beta-blockers and ACE inhibitors in patients with cancer.

Leave a Reply